Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSLNWA)

• Drug Name: WAY-255348 Drug Info
• Synonyms: WAY-255348; 872141-23-6; CHEMBL407848; WAY255348; KIOOLNRTWPFVHX-UHFFFAOYSA-N; GTPL8664; SCHEMBL1537222; BCP21063; ZINC29133439; BDBM50375827; WAY 255348; SB18886; KB-81484; 5-(7-fluoro-3,3-dimethyl-2-oxo-1H-indol-5-yl)-1-methylpyrrole-2-carbonitrile

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11543746
  TTD Drug ID: DMSLNWA

Molecule-Related Drug Atlas

Drug(s) Targeting Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Premature labour	JB00	Approved	[3]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[4]
Ulipristal	DMBNI20	Contraception	QA21	Approved	[5]
Etonogestrel	DMKA8J4	Contraception	QA21	Approved	[6]
Megestrol	DMDH9KX	Breast cancer	2C60-2C65	Approved	[7]
Segesterone acetate; ethinyl estradiol	DMFEGB0	Contraception	QA21	Approved	[8]
Norgestimate	DMYP4XC	Contraception	QA21	Approved	[6]
Dydrogesterone	DMAKIDV	Menstrual disorder	GA20.3	Approved	[9]
Medroxyprogesterone	DMBGWPH	Solid tumour/cancer	2A00-2F9Z	Approved	[9]
Ethynodiol diacetate	DMZM84R	Contraception	QA21	Approved	[10]

Drug(s) Targeting Androgen receptor messenger RNA (AR mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[11]
BAY 86-5044	DMRZLU4	Breast cancer	2C60-2C65	Phase 2	[12]
TRC-253	DMXI8CD	Prostate cancer	2C82.0	Phase 1/2	[13]
ISIS-AR	DM8P3N5	Prostate cancer	2C82.0	Phase 1	[14]
EZN-4176	DMNPS59	Prostate cancer	2C82.0	Phase 1	[15]
Eugenol	DM7US1H	Discovery agent	N.A.	Patented	[16]
RU-58841	DMMEAZ2	Acne vulgaris	ED80	Discontinued in Phase 1	[17]
Flavone	DMEQH6J	Discovery agent	N.A.	Investigative	[18]
Apigenin	DMI3491	Discovery agent	N.A.	Investigative	[18]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[18]

Drug(s) Targeting Mineralocorticoid receptor (MR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[19]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[20]
Fludrocortisone	DMUDIR8	Cerebral salt-wasting syndrome	5C72	Approved	[21]
Desoxycorticosterone acetate	DMS0AFE	Discovery agent	N.A.	Approved	[20]
Desoxycorticosterone pivalate	DMSA4B3	Addison disease	5A74.0	Approved	[22]
Drospirenone	DM1A9W3	Contraception	QA21	Approved	[23]
Spironolactone	DM2AQ5N	Congestive heart failure	BD10	Approved	[20]
Finerenone	DMM4FJ3	Diabetic nephropathy	GB61.Z	Phase 3	[24]
ZK-91587	DMJ94L0	Cardiovascular disease	BA00-BE2Z	Phase 2	[25]
Nerenone	DMBJ3GL	Diabetic nephropathy	GB61.Z	Phase 2	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor messenger RNA (AR mRNA)	TTKPW01	ANDR_HUMAN	Inhibitor	[2]
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Inhibitor	[2]
Progesterone receptor (PGR)	TTUV8G9	PRGR_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8664).
• [2] Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.
• [3] Clinical pipeline report, company report or official report of lipocine.
• [4] Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
• [7] Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
• [8] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [9] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
• [10] Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
• [12] Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [15] 2011 Pipeline of Santaris Pharma.
• [16] Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4.
• [17] Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
• [18] Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
• [19] Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [21] Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
• [22] Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
• [23] Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [25] ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).